Lenalidomide Accord

Lenalidomide, the active ingredient in Lenalidomide Accord, is an immunomodulatory imide drug (IMiD) presented as a tablet for oral use. It is used to treat multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is an immunomodulatory agent indicated for specific hematologic malignancies and related disorders.

- Multiple Myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease. - Myelodysplastic Syndromes (del(5q) cytogenetic abnormality): reduces transfusion dependence and may improve blood counts. - Mantle Cell Lymphoma: used in combination regimens to achieve disease control in adult patients.

Lenalidomide may cause a range of adverse reactions, from mild to severe. Monitoring and supportive care are essential during therapy.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: lowered neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet count leading to easy bruising. - Diarrhea: loose stools that may require hydration. - Nausea: upset stomach often managed with anti‑emetics. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: profound infection susceptibility. - Severe thrombocytopenia: risk of serious bleeding. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Hepatic failure: significant liver enzyme elevation or dysfunction.

Before initiating Lenalidomide, clinicians should assess several safety parameters and educate patients on risk mitigation.

- Blood Count Monitoring: perform complete blood counts regularly to detect cytopenias. - Thrombotic Risk Assessment: evaluate history of clotting disorders and consider prophylactic anticoagulation. - Renal Function Evaluation: adjust therapy if creatinine clearance is reduced. - Pregnancy Prevention: enforce strict contraception for both male and female patients of reproductive potential. - Concomitant Medication Review: avoid drugs that may exacerbate hematologic toxicity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lenalidomide interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Live vaccines: potential for uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal bleeding. - Digoxin: possible alteration of serum concentrations requiring monitoring.